Roche’s US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA
Basel, 25 August 2025 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today broke ground on its newest US manufacturing site in Holly Springs, North Carolina. This significant development marks the establishment of Genentech’s first manufacturing facility on the East Coast. The 65,000 m² facility is strategically designed to support production of the company’s future portfolio of metabolic medicines, including next-generation treatments for obesity.
Related Questions
How will the new manufacturing facility affect Genentech's and Roche's revenue forecasts and valuation?
What is the expected timeline for ramping up production of next‑generation obesity treatments at the North Carolina site?
How does this expansion compare to recent capacity upgrades by competitors in the metabolic medicines space and what could it mean for market share?